×

Foamix to Present Corporate Overview at the Oppenheimer 26th Annual Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview and business update at the Oppenheimer 26th Annual Healthcare Conference.

Presentation Details:
Title: Oppenheimer 26th Annual Healthcare Conference
Date: Tuesday, December 8
Time: 10:55am Eastern Time
Location: Westin New York Grand Central, New York City
Webcast: https://www.veracast.com/webcasts/opco/healthcare2015/79106250515.cfm

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Ilan Hadar, CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 ilan.hadar@foamixpharma.com U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 mrice@lifesciadvisors.com

Source:Foamix, Ltd.